Trials / Completed
CompletedNCT04557306
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
An Open, 3+3 Design With Dose De-escalation, Single-center, Phase 1 Trial to Evaluate Tolerabiility and Safety of Intravenously Administered CBT101, an Autologous Natural Killer Cell, in Patients Who Underwent Curative Surgery and Adjuvant Therapy for Solid Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- CHABiotech CO., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CBT101 cells, every 2 weeks | CBT101 cells, every 4 weeks |
| BIOLOGICAL | CBT101 cells, every 4 weeks | CBT101 cells, every 4 weeks |
Timeline
- Start date
- 2020-09-21
- Primary completion
- 2021-10-26
- Completion
- 2021-10-26
- First posted
- 2020-09-21
- Last updated
- 2024-04-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04557306. Inclusion in this directory is not an endorsement.